Open AccessReappraisal of glucocorticoids in castrate-resistant prostate cancer
Author(s) -
Oliver Sartor,
Christopher Parker,
Johann S. de Bono
Publication year - 2014
Publication title -
asian journal of andrology/asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.4103/1008-682x.133314
Subject(s) - enzalutamide , prostate cancer , androgen receptor , medicine , glucocorticoid receptor , cancer research , cancer , androgen , prostate , oncology , disease , glucocorticoid , androgen deprivation therapy , hormone
Recent reports and discussions of preclinical prostate cancer models have emphasized the possibility that enzalutamide resistance may be mediated by glucocorticoid receptors (GR). [1],[2] In both in vitroand xenograft animal studies, it is possible to show that the GR is up-regulated in prostate cancer cell lines and that dexamethasone reverses enzalutamide induced growth inhibition. In these model systems, GR agonists can induce a subset of androgen receptor target genes including prostate-specific antigen. These investigators also report a correlation between GR expression in patient-derived prostate cancer specimens and clinical response to enzalutamide. The authors discuss the possibility that these findings have important clinical relevance. We note that the current clinical evidence for GR mediating drug resistance or disease progression in patients with castrate-resistant prostate cancer (CRPC) is very limited at best